OncoMatch/Clinical Trials/NCT07671339
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Is NCT07671339 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1 trial studies multiple treatments including ELI-002 7P and Tislelizumab for pancreatic cancer.
Treatment: ELI-002 7P · Tislelizumab · mFOLFIRINOX — The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a KRAS mutation. In addition, the researchers are doing this study to find out whether the study treatment is effective against PDAC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: KRAS g12a
Required: KRAS g12c
Required: KRAS g12d
Required: KRAS g12r
Required: KRAS g12s
Required: KRAS g12v
Required: KRAS g13d
Disease stage
Required: Stage RESECTABLE, BORDERLINE RESECTABLE (other)
Excluded: Stage III, IV
Patients must have resectable or borderline resectable localized disease as defined by NCCN Guidelines v2.2025. Staging CT or MRI ... must be negative for metastatic disease. Locally advanced unresectable PDAC (per NCCN v2.2025) ... [excluded]. Metastatic PDAC [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: TNF receptor agonist (OX40, CD27, CD137, GITR)
Prior treatment with TNF receptor agonists (OX40, CD27, CD137/4-1BB, GITR)
Cannot have received: checkpoint inhibitor (anti-CTLA-4, anti-PD-1, anti-PD-L1)
prior checkpoint inhibitor therapy (anti-CTLA-4, anti-PD-1, anti-PD-L1)
Lab requirements
Blood counts
anc ≥1,500/mm³; platelets ≥100,000/mm³; hemoglobin ≥8.0 g/dl
Kidney function
creatinine clearance ≥50 ml/min (cockcroft-gault formula or 24-hour urine collection)
Liver function
total bilirubin ≤1.5 × uln (gilbert's syndrome allowed up to ≤3 × uln); ast and alt ≤3 × uln; albumin ≥2.5 g/dl
Cardiac function
patients with known cardiac disease or prior exposure to cardiotoxic agents should undergo risk assessment per nyha classification; patients must be class or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07671339 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior TNF receptor agonist, checkpoint inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12a is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS g12c is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS g12d is a required biomarker for enrollment.
What disease stage is eligible?
Stage RESECTABLE or BORDERLINE RESECTABLE is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages